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Abstract 
Venoarterial (VA) extracorporeal life support (ECLS) for neonatal respiratory failure is 
associated with increased mortality compared to venovenous (VV) ECLS. It is unclear if 
this is a causal relationship or reflects differences in baseline disease severity between 
infants managed with these two strategies. Our objective was to identify clinical variables 
associated with the preferential selection of VA over VV ECLS, as these may confound 
the association between VA ECLS and increased mortality. We identified documented 
indications for preferential VA selection through chart review. We then assessed how the 
presence of common indications impacted mortality. 39 cases met eligibility. Severity of 
hypotension/degree of inotropic support and ventricular dysfunction on echocardiogram 
prior to cannulation were the most common specific indications for preferential VA 
ECLS. Mortality was 12.5% when neither high inotropic support nor ventricular 
dysfunction was present. Mortality rose to 20% with high inotropic support and 25% with 
ventricular dysfunction present alone and to 50% when both were present. We conclude 
that severe hypotension and ventricular dysfunction prior to ECLS cannulation are 
common indications for VA ECLS that likely influence survival. Research assessing the 
impact of ECLS cannulation mode on survival should adjust for baseline differences 
between groups for these important variables.  
Keywords: extracorporeal membrane oxygenation; infant, neonate; respiratory 
insufficiency; intensive care units, neonatal; persistent fetal circulation syndrome. 
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Providers caring for infants with refractory respiratory failure employ venoarterial (VA) 
or double-lumen venovenous (VV) cannulation to provide life-saving extracorporeal life 
support (ECLS). Each mode has distinct advantages and disadvantages that may 
influence patient outcomes.
1, 2 
A notable advantage of VV is single vessel support without 
need to ligate the right common carotid artery - a disadvantage of VA. However, only 
VA provides both gas exchange and circulatory support. VV does not provide the latter, 
relying on native cardiac output for circulation. While sparing the carotid artery is 
desirable, VA is often preferentially employed when the infant’s clinical presentation 
questions the adequacy of native cardiac output, suggesting greater disease severity. 
These important baseline differences bias comparisons between ECLS modes on 
important patient outcomes. Data from the Extracorporeal Life Support Organization 
(ELSO) registry show 13% greater in-hospital mortality for infants receiving support 
with VA rather than VV ECLS.
3
 While this may reflect harm caused by VA, it may 
instead simply reflect a strong association between baseline disease severity and both the 
likelihood of VA selection and death.  
The primary aim of this study was to characterize the clinical variables that result 
in selection of VA ECLS by identifying documented indications for its preferential use in 
a cohort of neonates with respiratory failure. The second aim was to evaluate how the 
presence of these clinical variables influences the outcome of in-hospital mortality. Our 
objective was to identify clinical variables that require consideration when comparing 
outcome differences between ECLS modes in neonates with respiratory failure. 
Methods 
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We performed a single-center observational study. A descriptive study design was 
followed by a retrospective cohort design for our primary and secondary aims, 
respectively. Our institutional review board approved the study.  
Population 
 All neonates without congenital anomalies, born at greater than 35 weeks 
gestational age and undergoing VA ECLS for respiratory failure within 14 days of life at 
the Children’s Hospital of Philadelphia between January of 2001 and August of 2014 
were included. VV or VA modes were considered on a case-by-case basis. Study 
exclusions were congenital anomalies, discovered before or after birth. This included 
congenital heart disease, congenital diaphragmatic hernia (CDH) or genetic diseases 
without gross anatomic anomalies, such as alveolar capillary dysplasia. Although CDH 
accounts for many ECLS neonatal respiratory failure cases, we chose to exclude this 
population for two reasons.  First, CDH infants differ from other neonates in their 
underlying pathophysiology. Second, our institution routinely provides VA rather than 
VV ECLS for CDH. As such, evaluation of this diagnostic subgroup was not applicable 
to the objective of characterizing the indications resulting in the preferential use of VA 
over VV ECLS.  
Data Collection  
Initial screening for eligibility was performed through a database containing all 
ECLS cases performed in our neonatal unit. This database includes primary diagnosis, 
age at cannulation and mode of ECLS support. Following exclusions, two authors 
performed a detailed chart review to confirm eligibility and identify the indication for 
preferential use of VA ECLS.  
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A primary indication for VA ECLS was assigned only when medical documentation 
clearly described the reasoning for selection of this mode. Instances in which a primary 
indication was not clearly documented were categorized as “unclear or not specified.” An 
exception was made when cannulation occurred emergently during ongoing chest 
compressions for cardiopulmonary resuscitation – based on our clinical practice we felt 
this to be a self-evident indication without need for explicit documentation justifying the 
selection of VA.   
For the second aim, we assessed how the presence of common VA indications 
impacted in-hospital mortality. All cases were assessed for the presence of pre-
cannulation variables most commonly found to be VA indications. Presence of the 
variable was determined by pre-specified definitions (see section “1.3 Definitions”) 
irrespective of whether or not provider documentation suggested this was the indication 
for VA selection. For example, a patient may have been described as having undergone 
VA ECLS due to the degree of inotropic support yet not meet pre-defined criteria for 
“High Inotropic Support” for this second objective. Additional variables collected from 
the ELSO registry and/or through medical chart review included birth weight in 
kilograms, gestational age in weeks, sex, race, one minute Apgar score, primary 
diagnosis, oxygenation index and in-hospital mortality. Occasional missing data for one 
minute Apgar score and oxygenation index are reflected within the variable row heading 
in Tables II and III.  
Definitions  
For the characterization of primary indications, “Severity of 
Hypotension/Inotropic Support” includes cases in which medical documentation 
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indicated that the severity of hypotension and/or degree of inotropic support was the 
primary reason for the selection of VA over VV ECLS. “Ventricular Dysfunction on 
Echocardiogram” includes all cases in which documentation indicated that findings from 
an echocardiogram reporting ventricular dysfunction were the primary indication for VA. 
A variety of additional specific clinical circumstances were documented as primary 
indications without appearing more than twice. The qualifying term “Clinical/Not 
Otherwise Specified (NOS)” indicates clinical impressions that were clearly specified as 
the indication for VA ECLS but without elaboration as to the objective findings that 
resulted in that clinical impression. “VV Not Attempted Due To Patient Size” specifies 
cases in which VA was used without an attempt to place a VV cannula due to patient 
size, while “VV Attempted, Unable to Insert” denotes cases in which VA was used 
following a failed attempt to place a double-lumen VV cannula.   
For the second aim of evaluating the impact of common indications for VA on mortality, 
“High Inotropic Support” was defined as dopamine monotherapy in excess of 15 
micrograms per kilogram per minute or use of multiple inotropic agents. This was a 
pragmatic definition reflective of our institution’s typical practice of using dopamine 
monotherapy as a first line agent, followed by dose escalation and/or use of additional 
medications for refractory hypotension. “Ventricular Dysfunction on Echo” was noted as 
present when echocardiography performed prior to cannulation documented moderate, 
moderate to severe or severely diminished ventricular systolic shortening or reported 
“poor” function or frank “dysfunction” for either right or left ventricle. In contrast, 
documentation of mild or mild to moderately diminished ventricular systolic shortening 
or reported “low normal”, “mild dysfunction” or “normal” function for both ventricles 
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did not meet criteria.  On the basis of the presence of these two common indications, the 
variable “VA Indications Status” was generated to classify subjects as “Neither”, “High 
Inotropic Support Only”, “Ventricular Dysfunction Only” or “Both” for subsequent 
analysis.  
Statistical Analysis 
Data was summarized using frequency counts and percentages, means and 
standard deviations for parametric data and medians and interquartile ranges for non-
parametric data. We compared “VA Indications Status” groups as follows: unadjusted 
univariate comparisons of continuous dependent variables were performed with analysis 
of variance for parametric data and Kruskal-Wallis for non-parametric data, categorical 
outcomes were performed with Fisher’s exact test. Multivariate logistic regression was 
used to assess the adjusted impact of “VA Indications Status” on in-hospital mortality. 
Model selection assessed all collected variables as candidate explanatory covariates. 
Variables resulting in a likelihood ratio test with p < 0.20 when added to a model 
restricted to “VA Indications Status” were included in the final multivariate model. An 
alpha level of p < 0.05 was considered statistically significant. Analyses were performed 
using STATA/IC 13.0 software (Stata Corp., College Station, Texas.)   
Results  
273 infants underwent ECLS in our neonatal intensive care unit within the study 
period.  Using our clinical database to screen, we excluded 135 infants with congenital 
anomalies (including CDH) and 15 infants older than 14 days at ECLS cannulation. Of 
the remaining 123, we excluded the 80 (65%) for which VV ECLS was selected. Chart 
review of the remaining 43 cases resulted in 4 additional exclusions for congenital 
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anomalies, resulting in a study cohort of 39 infants for whom VA ECLS was selected. 
This process is summarized in Figure 1.  
The results of our first aim are displayed in Table I. A primary indication for the 
selection of VA ECLS was clearly documented in 26 of 39 (69%) cases. Specific clinical 
concerns resulted in VA selection in 23 (59%). Of these, concerns regarding the severity 
of hypotension and/or degree of required inotropic support (6 cases, 15%) and evidence 
of ventricular dysfunction on an echocardiogram prior to cannulation (4 cases, 10%) were 
the most common specific clinical indications for VA selection. Several other specific 
clinical indications documented twice or less are listed in Table I. Four cases (10%) 
required VA ECLS as part of ongoing cardiopulmonary resuscitation with chest 
compressions. Technical size limitations associated with the use of a double lumen VV 
cannula resulted in use of VA ECLS in 4 (10%) cases. Of these, 3 were unsuccessful 
attempts to place a VV cannula; in the remaining case no attempt was made on the basis 
of patient size. The remaining 12 (31%) cases lacked clear medical documentation 
describing the rationale for VA selection. Baseline characteristics of infants undergoing 
VA ECLS for clinical, technical or unspecified indications are provided in Table II.  
There were no statistically significant differences between groups. All four infants for 
whom VA ECLS was chosen because of technical limitations survived. In contrast, 25% 
(3/12) of infants for whom a primary indication was unspecified and 35% (8/23) of 
infants for whom a clinical concern resulted in VA ECLS, died.  
For our second aim, we compared infants of the basis of the absence or presence 
of high inotropic support and ventricular dysfunction on echocardiogram. Baseline 
characteristics between groups are displayed in Table III. There were no statistically 
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significant differences. The impact of VA ECLS on mortality is depicted in Figure 2. 
Mortality was 12.5% when neither high inotropic support nor ventricular dysfunction was 
present. Mortality rose to 20% with high inotropic support in isolation and to 25% with 
ventricular dysfunction in isolation. The presence of both concurrently was associated 
with 50% mortality.  A mortality outcome was ascertained for all subjects, with no 
missing data. Gestational age, birth weight and Apgar score at one minute met criteria for 
covariate inclusion in the multivariate analysis. Increasing birth weight and gestational 
age were associated with a trend towards increased mortality risk, while increasing Apgar 
score was associated with a trend towards decreased mortality. The impact of these 
variables and VA ECLS indications on in-hospital mortality in both univariate and 
multivariate adjusted analysis is summarized in Table IV.  
Discussion 
To our knowledge, this is the first study systematically characterizing the clinical 
variables resulting in the selection of VA ECLS and assessing the impact of their 
presence on neonatal mortality. We found that clinical concerns surrounding the degree 
of cardiorespiratory compromise were the most common indications, with the severity of 
inotropic refractory hypotension and evidence of ventricular dysfunction on 
echocardiogram being the two most common specific indications.  
No infant placed on VA ECLS for technical indications died, compared to 35% of 
infants placed on VA ECLS due to clinical concerns. As depicted in Figure 2, the 
presence of either high inotropic support or echocardiographic evidence of ventricular 
dysfunction in isolation was associated with an approximate doubling in the risk of 
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mortality. When both were present, the mortality risk was four-fold.  Adjustment for 
confounding variables only further amplified the effect size of these associations.  
Our results are important for two reasons. First, they have implications for 
survival prognostication. Clinicians and parents should appreciate that factors present at 
the time of cannulation may considerably influence mortality. Second, our results have 
important implications for further clinical research on this topic.  
It remains unclear if the use of VA over VV ECLS causes increased mortality. 
Reports of a survival benefit for VV when not accounting for group differences are 
challenged by reports suggesting its absence when accounting for baseline group 
differences or restricting the study cohort to similar patients.
4-7
 Recently, a large 
retrospective report of the ELSO registry by Smith and colleagues shows persistence of 
an independent mortality risk associated with VA mode after adjustment for baseline 
differences between groups through multivariate logistic regression.
8
 This contemporary, 
well-designed analysis may represent the best approximation of any true difference. 
However, the study authors acknowledge that a persistent confounding bias likely exists. 
Authors of recently published reviews agree that available data is limited by the presence 
of confounding bias, and further, that currently available ELSO registry data are unable 
to provide insight into whether differences between VA and VV ECLS are “due to patient 
selection, severity of illness, or an inherent benefit of the particular mode.”2,3 These 
limitations are due to “residual confounding” – persistent bias from unaccounted 
differences between groups that are either not collected or collected with insufficient 
precision to discriminate important differences. Our results highlight two likely principal 
sources of residual confounding. With respect to degree of inotropic refractory 
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hypotension, registry data identifies inotropic agents used prior to ECLS, but does not 
provide more precise information, such as medication dose. The vast majority of neonates 
requiring ECLS receive some degree of inotropic support.
9
 Thus, useful discrimination 
between high and low risk groups on the basis of this variable requires characterization 
beyond the mere absence or presence of an inotropic agent. The registry does not collect 
data on pre-cannulation echocardiographic findings. We found that the extent of inotropic 
refractory hypotension and ventricular dysfunction prior to cannulation are the most 
common drivers of VA selection and influence survival. Thus, accounting for baseline 
differences in these characteristics is critical to any unbiased approximation of mortality 
differences.   
Despite a possible association with increased mortality, increased central nervous 
system injury and concerns regarding the long-term health consequences of carotid artery 
ligation, VA remains the most commonly used ECLS mode in our study population. 
Between 2001 and 2010, in excess of 50% of cases reported to the ELSO registry were 
performed with VA.
8
 It is therefore likely that VA is often used for cases amenable to VV 
ECLS. Better characterizing unbiased outcome differences would inform decision 
making for clinicians uncertain about the benefit or harm of using VA ECLS judiciously.  
We speculate that even in the absence of technical limitations, there exists a 
population of infants for whom VA ECLS, and the direct circulatory support it provides, 
is beneficial. The challenge remains to identify which patient will benefit. Published 
guidelines have suggested that hemodynamic instability including hypotension, high 
doses of inotropic drugs and severe myocardial dysfunction are contraindications for VV 
ECLS.
10
 However, successful VV ECLS use despite significant hypotension and 
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inotropic support has been reported in several studies,
 
most notably a report by Roberts 
and colleagues in which pre-cannulation inotropic support scores were assigned to all 
infants.
9, 11,12
 We are not aware of published reports of VV ECLS in a cohort of neonates 
with echocardiographic evidence of ventricular dysfunction prior to cannulation. 
However, Strieper and colleagues report improvement in ventricular dysfunction 
following initiation of VV ECLS in neonates with borderline left ventricular function.
13
 
Characterizing the population for whom VA ECLS is beneficial begins with better 
understanding the variables that result in its selection.  
 Our study has important limitations. As with all chart reviews, the accuracy of our 
data is limited by omissions and ambiguities in clinical documentation, resulting in a risk 
for information bias. In excess of thirty percent of our cases lacked clear documentation 
of the indication for VA selection. Further, many of our variables were susceptible to 
misclassification bias. This decreases the validity of our primary objective – 
characterizing indications for VA ECLS in this population. Similarly, misclassification 
bias could decrease the accuracy of our secondary aim: to evaluate how the presence or 
absence of these variables influenced mortality. Our definitions for high inotropic support 
and ventricular dysfunction do not represent standardized nor validated definitions, but 
rather pragmatic classifications reflective of our practice. Clinical echocardiogram reports 
may be influenced by the quality of the images obtained, as well as variability between 
readers in interpretation and reporting parameters. Despite these limitations, the resulting 
differences in mortality on the basis of the presence or absence of these definitions 
suggest a measure of validity for what they attempt to capture: evidence of increasing 
disease severity. As a report of a single center experience, our results have limited 
Copyright © 2016 by the American Society for Artificial Internal Organs
AC
CE
PT
ED
14 
 
generalizability. Despite a high neonatal ECLS case volume and evaluation over a 14-
year period, our sample size resulted in inadequate power to detect a statistically 
significant association between mortality and the presence of high inotropic support, 
ventricular dysfunction or both despite clinically meaningful increases in mortality 
associated with these variables (Figure 2 and Table IV).  
 Performing a randomized controlled trial assessing VA versus VV ECLS would 
be an ideal approach for obtaining an unbiased estimate of the effect of these modes on 
important patient outcomes. However, the likelihood of implementing such a trial is low. 
In its absence, collaborative, multi-center, prospective studies with objective and well-
defined variables are needed to better approximate the risk and benefits of VA versus VV 
ECLS. Such studies should anticipate and account for the high risk of confounding bias 
through the collection of variables that may be associated with both the selection of 
cannulation mode and important outcomes such as death. Our findings suggest that the 
degree of inotropic refractory hypotension and echocardiographic ventricular dysfunction 
are critical variables for consideration. 
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Table and Figure Legends 
Figure 1. 
ECLS =  extracorporeal life support, VV = venovenous. 
Figure 2.  
Neither and both refer to absence or presence of both high inotropic support and 
ventricular dysfunction on echocardiogram, respectively. VA, venoarterial; ECLS, 
extracorporeal life support. Differences in mortality relative to “Neither” (reference) do 
not reach statistical significance in adjusted analyses; for “Both” p = 0.05 but is not < 
0.05 (see Table 4).  
Table I.  
NOS = not otherwise specified, VV = venovenous. 
Table II.  
IQR, interquartile range; SD, standard deviation; MAS, meconium aspiration syndrome; 
PPHN, persistent pulmonary hypertension of the newborn; RDS, respiratory distress 
syndrome; NOS, not otherwise specified, PNA, pneumonia. p > 0.05 for all comparisons. 
Table III.  
IQR, interquartile range; SD, standard deviation; MAS, meconium aspiration syndrome; 
PPHN, persistent pulmonary hypertension of the newborn; RDS, respiratory distress 
syndrome; NOS, not otherwise specified, PNA, pneumonia. p > 0.05 for all comparisons. 
Table IV. 
OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; VA, venoarterial; 
ECLS, extracorporeal life support 
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Table I. Specified primary indications for selection of venoarterial extracorporeal 
life support  
 
Primary Indication Frequency Percent 
Total 39  
Specific Clinical Concerns: 23 59.0 
Severity of Hypotension/Inotropic Support 6 15.4 
Ventricular Dysfunction on Echocardiogram 4 10.3 
Severity of Pulmonary Hypertension, Clinical/NOS 2 5.1 
Severity of Ductal Shunt Gradient 1 2.6 
Poor Cardiac Function, Clinical/NOS 1 2.6 
Respiratory and Cardiac Failure, Clinical/NOS 1 2.6 
Right Ventricular Dilatation on Echocardiogram 1 2.6 
Concern for Premature Ductal Closure 1 2.6 
Degree of Hypoxemia 1 2.6 
Concern for Unclear Disease Etiology 1 2.6 
Active CPR/Chest Compressions 4 10.3 
Technical Size Limitations: 4 10.2 
VV Not Attempted Due To Patient Size 1 2.6 
VV Attempted, Unable To Insert 3 7.7 
Unclear or Not Specified 12 30.8 
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Table II. Baseline characteristics by documented primary indication for 
venoarterial extracorporeal life support    
 
Total Clinical Unspecified Technical 
Subjects 39 23  12 4 
Birth gestational age (weeks) 
   
 
Median (IQR) 39.0 (37.0-40.0) 39.0 (37.4-40.0) 38.5 (36.5-39.5) 39.5 (37.5-40.2) 
Birth weight (kilograms) 
   
 
Median (IQR) 3.21 (2.80-3.67) 3.21 (2.80-4.18) 3.34 (2.75-3.59) 3.16 (2.51-3.50) 
Sex 
   
 
Male 24 (62%) 14 (61%) 8 (67%) 2 (50%) 
Female 15 (38%) 9 (39%) 4 (33%) 2 (50%) 
Race 
   
 
White 18 12 (52%) 4 (33%) 2 (50%) 
Black 15 7 (30%) 6 (50%) 2 (50%) 
Other 6 4 (17%) 2 (17%) 0 (0%) 
One minute Apgar score n = 37 n = 22 n = 11 n = 4 
Mean (SD) 4.5 (2.9) 4.5 (2.7) 4.1 (3.3) 5.0 (3.6) 
Diagnosis 
 
   
MAS 7 (18%) 3 (13%) 3 (25%) 1 (25%) 
PPHN 20 (51%) 13 (57%) 6 (50%) 1 (25%) 
Other (RDS, Respiratory Failure NOS, 
PNA/Sepsis) 
12 (31%) 7 (30%) 3 (25%) 2 (50%) 
Oxygenation Index n = 30 n = 16 n = 11 n = 3 
Median (IQR) 43.3 (34.5-61.5) 42.3 (26.2-54.2) 53.2 (39.2-72.2) 36.7 (25.6-80.0) 
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Table III. Baseline characteristics by presence of common indications for 
venoarterial extracorporeal life support.    
 
Neither  
High Inotropic  
Support Only 
Ventricular 
Dysfunction Only 
 
Both  
Subjects (n = 39) 8 (21%) 15 (38%) 4 (10%) 12 (31%) 
Birth gestational age (weeks) 
   
 
Median (IQR) 39.2 (37.5-40.0) 38.0 (36.5-40.0) 39.5 (38.0-40.5) 39.2 (37.8-40.0) 
Birth weight (kilograms) 
   
 
Median (IQR) 3.35 (3.01-4.12) 2.99 (2.79-3.59) 3.33 (2.99-4.30) 3.56 (2.60-3.74) 
Sex 
   
 
Male 5 (63%) 10 (67%) 2 (50%) 7 (58%) 
Female 3 (38%) 5 (33%) 2 (50%) 5 (42%) 
Race 
   
 
White 4 (50%) 7 (47%) 0 (0%) 7 (58%) 
Black 4 (50%) 5 (33%) 4(100%) 2 (17%) 
Other 0 (0%) 3 (20%) 0 (0%) 3 (25%) 
One minute Apgar score n = 8 n = 14 n = 4 n = 11 
Mean (SD) 3.6 (2.8) 4.8 (2.8) 5.5 (3.7) 4.3 (3.1) 
Diagnosis 
 
   
MAS 3 (38%) 2 (13%) 1 (25%) 1 (8%) 
PPHN 3 (25%) 8 (53%) 2 (50%) 7 (58%) 
Other (RDS, Respiratory Failure NOS, 
PNA/Sepsis) 
2 (38%) 5 (33%) 1 (25%) 4 (33%) 
Oxygenation Index n = 7 n = 10 n = 4 n = 9 
Median (IQR) 44.2 (35.1-80.0) 54.6 (45.0-72.2) 31.7 (25.7-45.5) 39.2 (28.8-42.6) 
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Table IV. Common indications for VA ECLS: association with in-hospital mortality 
in univariate and multivariate analysis.   
 
  
Mortality Effect Estimate OR (95% CI) aOR (95% CI) p-value 
 Univariate Multivariate 
Common VA ECLS Indications    
Neither High Inotropic Support or Ventricular Dysfunction Reference Reference - 
High Inotropic Support Only 1.75 (0.15-20.2) 6.89  (0.29-165) 0.23 
Ventricular Dysfunction Only 2.33 (0.11-51.0) 2.05 (0.47-89.8) 0.71 
Both High Inotropic Support and Ventricular Dysfunction 7.00 (0.64- 75.7) 30.0 (0.98-913) 0.05 
Multivariate Model Covariates: 
  
 
One Minute Apgar Score - 0.69 (0.45 – 1.03) 0.07 
Gestational Age (per week) - 1.56 (0.78-3.25) 0.20 
Birth Weight (per kilogram) - 3.13 (0.96 – 10.2) 0.06 
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Figure 1. 
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Figure 2. 
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